Spinal cord injury (SCI) is a devastating condition afflicting over 13,000 people annually in North America and is an important cause of mortality and neurological morbidity1.
Although early pharmacological intervention after SCI with methylprednisolone2,3 or GM-1 ganglioside4 results in modest neurological improvement, the overall impact of these treatments remains minimal. Therefore, novel therapeutic approaches are required to improve the neurological outcome of these patients.
Continue reading